Yahoo · Aug 13, 2026
Sera Prognostics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Sera Prognostics, Inc.'s Q2 2026 earnings call
SE
NASDAQ · SERA
Sera Prognostics, Inc.
Healthcare · Medical - Diagnostics & Research
$2.03
Up+$0.03 (+1.23%)
Updated Sep 14, 2026, 3:12 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 127.56M
- P/E ratio
- -5.15
- Dividend yield
- 0.00%
- 52-week range
- $1.56 – $2.46
- Volume
- 26.36K
- Avg. volume
- 44.27K
Price performance
SERA price history
1M range · 19 trading sessions · Daily adjusted prices
SERA closed at $2.03 after 19 trading sessions, up 4.10% for the selected period.
- Last close
- $2.03
- Period change
- +4.10%
- Period low
- $1.93
- Period high
- $2.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.05 | $2.055 | $1.9969 | $2.03 | 26.36K |
| Sep 10, 2026 | $2.00 | $2.06 | $1.995 | $2.05 | 72.09K |
| Sep 9, 2026 | $2.01 | $2.06 | $2.00 | $2.00 | 8.25K |
| Sep 8, 2026 | $2.00 | $2.04 | $1.98 | $2.01 | 64.07K |
| Sep 4, 2026 | $2.00 | $2.05 | $1.97 | $2.02 | 10.53K |
| Sep 3, 2026 | $2.03 | $2.06 | $1.98 | $1.98 | 15.26K |
| Sep 2, 2026 | $2.01 | $2.18 | $1.97 | $2.01 | 15.38K |
| Sep 1, 2026 | $2.09 | $2.16 | $2.08 | $2.08 | 14.67K |
| Aug 31, 2026 | $2.08 | $2.1772 | $2.08 | $2.12 | 9.52K |
| Aug 28, 2026 | $2.07 | $2.09 | $2.05 | $2.07 | 23.12K |
| Aug 27, 2026 | $2.11 | $2.20 | $1.98 | $2.03 | 51.44K |
| Aug 26, 2026 | $2.18 | $2.18 | $2.09 | $2.09 | 7.28K |
| Aug 25, 2026 | $2.12 | $2.21 | $2.12 | $2.18 | 17.84K |
| Aug 24, 2026 | $2.14 | $2.2113 | $2.06 | $2.18 | 19.38K |
| Aug 21, 2026 | $2.09 | $2.16 | $2.085 | $2.14 | 14.57K |
| Aug 20, 2026 | $1.99 | $2.10 | $1.99 | $2.10 | 30.86K |
| Aug 19, 2026 | $2.04 | $2.05 | $1.9801 | $1.99 | 26.26K |
| Aug 18, 2026 | $2.00 | $2.00 | $1.915 | $1.93 | 9.49K |
| Aug 17, 2026 | $1.94 | $2.025 | $1.94 | $1.95 | 26.94K |
Latest SERA news
The latest Smart Investors Daily articles mentioning SERA.
Stock researchCompany · Overview
SERA research
Overview
Company profile and research snapshot.
Company profile
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $2.81
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 4, 2026 | Craig-Hallum | Buy | — |
| Aug 10, 2023 | Citigroup | Neutral | — |
| Nov 10, 2022 | Citigroup | Neutral | — |
| Aug 29, 2022 | Oppenheimer | Outperform | — |
| Apr 27, 2022 | Berenberg | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Sera Prognostics Inc (SERA) (Q2 2026) Earnings Call Highlights: Payer Momentum Builds with ...
Despite minimal revenue, Sera Prognostics advances commercial strategy with new payer programs and a strengthened cash runway through 2029.
Yahoo · Aug 13, 2026
Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform. Revenue for the quarter ended June 30 was $30,000, compared
Yahoo · Aug 12, 2026
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
Sera Prognostics (SERA) delivered earnings and revenue surprises of -28.57% and -76.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
